Board of Directors

Maurie Stang

Non-Executive Chairman

Mr Stang was Executive Director and Chairman of Nanosonics Limited from 14 November 2000 to March 2007. He has been Non-Executive Director and Chairman since March 2007. Mr Stang co-founded and is a director of a number of leading healthcare distribution and biotechnology companies. His business activities and experience span the successful commercialisation of intellectual property across global markets. He has a track record of launching and commercialising a broad range of medical and dental devices worldwide.

Ron Weinberger BSc (Hons), PhD

President Technology Development/Commercialisation

Dr Weinberger joined the Company in August 2004 and was appointed as Executive Director in July 2008. Dr Weinberger was appointed as Chief Executive Officer in May 2011. Dr Weinberger has executive responsibility for the overall leadership of the business and the implementation of its strategies. Since 2004 Dr Weinberger has been in a range of roles leading product development and overseeing manufacturing and operations. He is an intellectual property expert and entrepreneur in the development of novel technologies. Dr Weinberger is co-inventor of several of Nanosonics’ key technology patents which underpin the Company’s platform technology.

Richard England FCA, MAICD

Non-Executive Director

Mr England is a chartered accountant and professional non-executive director. He has over 30 years’ experience in accounting and financial services, as well as considerable experience with early stage biotech companies. From 1998 to 2006 Mr England was chairman and a director of Gropep Limited, an Australian biotech company which grew successfully from start-up to be acquired in 2006 by the Danish company Novozymes A/S. From 2003 to 2007, Mr England was a director of ITL Limited, an Australian company which designs and manufactures medical devices and procedure packs for global healthcare markets.

David Fisher BRurSc (Hons), MAppFin, PhD, FFin

Non-Executive Director

Dr Fisher has over 25 years' experience, including substantial operating experience in the biotechnology and healthcare industry in Australia and overseas. He held senior positions with Pharmacia AB in Sweden and was CEO in Australia of Peptech Limited (now Arana Therapeutics Limited). He is Managing Director of Brandon Capital Management Pty Ltd, a venture capital provider and investor in Nanosonics. He is also a director of Australian Biomedical Fund No 1 Ltd, Australian Biomedical Fund No 2 Ltd, and Australian Biotechnology and Healthcare Fund No 3 Ltd.

Michael Kavanagh BSc, MBA (Advanced)

CEO & President

Mr Michael Kavanagh joined Nanosonics as CEO & President effective 21st October 2013.  Michael is a highly experienced executive with over 20 years of international commercial experience in the healthcare market having held local, regional and global roles in Medical Device and Pharmaceutical industries. He holds a BSc Degree from University College Dublin and an MBA (Advanced) from the University of Queensland. Before joining Nanosonics, Michael was Senior Vice President of Global Marketing for the major medical device company Cochlear Limited, a position he held for more than 10 years.